Similar to radiolabeled TSPO ligands, N-AS might be considered to diagnose neuroinflammation in early AD stages, in addition to its potential therapeutic use, based on two results: (1) In PK profiling of N-AS, a high concentration of N-AS was maintained in plasma and brain, and N-AS had high-distribution to the brain; and (2) N-AS had high binding affinity and induced high-level acetylation of the elevated COX2, prior to observing Aβ deposits in APP/PS1 microglia. The gene discussed is APP; the disease is Alzheimer disease.